Russia tightens responsibility for sale and production of counterfeit drugs

30 July 2014
moscow-big

The Russian government has significantly tightened responsibility for the sale and production of counterfeit drugs, through the introduction of amendments relating to activities in the national Criminal Code.

It is planned that the maximum penalty for the production of counterfeit drugs will involve the imposition of a fine in the amount of 5 million roubles ($150,000), and in some cases up to 12 years’ imprisonment.

According to Alexander Prokopiev, a member of the Russian Parliament (State Duma) and one of the initiators of the new amendments, the current Russian legislation in the field of pharmaceuticals, so far, has been ineffective to combat counterfeiters and has not always allowed to prosecute suspects and was associated with complex proof procedure.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical